Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - patients' views of early cessation of therapy


D'Souza, R., Main, J., Crossey, M., Rosenberg, W., Murray-Lyon, I.M., Hayward, C. and Foster, G.R. (2005) Discontinuation of pegylated interferon plus ribavirin in patients who are not responding to therapy - patients' views of early cessation of therapy. Alimentary Pharmacology and Therapeutics, 21, (1), 43-47. (doi:10.1111/j.1365-2036.2004.02295.x).

Download

Full text not available from this repository.

Description/Abstract

Background: Current therapy for chronic hepatitis C infection involves a course of pegylated interferon and ribavirin. Patients who do not show a virological response after 12 weeks of therapy have a low probability of sustained virological response and it is therefore recommended that such patients stop treatment.

Aim: To assess patients' views of early treatment cessation.

Methods: We conducted a open-labelled study in three UK centres, in which patients with biopsy-proven chronic hepatitis C requiring therapy were offered the choice of a full course of therapy with 40 kDa pegylated interferon-α 2a plus ribavirin (24 or 48 weeks depending on viral genotype) or early cessation if therapy had failed after 12 weeks.

Results: Ninety-five participants were enrolled and the majority (69%) did not wish to discontinue therapy even if it had low probability of success. In this unselected UK population, very few patients (4%) did not achieve an early virological response with the 40-kDa pegylated interferon-α 2a plus ribavirin and two of the four early virological non-responders decided to continue therapy.

Conclusion: Early discontinuation of 'ineffective' anti-viral therapy may prove less popular with patients than with health care providers, and further patient-directed education regarding the cost-effectiveness of therapy will be needed if early discontinuation of unsuccessful therapy is to be accepted by patients.

Item Type: Article
ISSNs: 0269-2813 (print)
Related URLs:
Subjects: Q Science > QR Microbiology > QR355 Virology
R Medicine > RM Therapeutics. Pharmacology
Divisions: University Structure - Pre August 2011 > School of Medicine > Infection, Inflammation and Repair
ePrint ID: 27010
Date Deposited: 25 Apr 2006
Last Modified: 27 Mar 2014 18:15
URI: http://eprints.soton.ac.uk/id/eprint/27010

Actions (login required)

View Item View Item